Mesoblast enters $125M five-year credit facility

Accepted by SEC EDGAR 11/10/2026 - 06:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Mesoblast Limited (MESO) reported FY2026 net revenue of US$115 million and gross profit on total sales, excluding amortization expense, of US$110 million. It entered a US$125.0 million, five-year non-dilutive credit-line facility, consolidating and retiring two higher-cost facilities. Mesoblast completed enrollment of 350 patients in its Phase 3 chronic low back pain trial; a readout is targeted for the second half of calendar 2027, followed by a planned Biologics License Application filing. The company also reported FDA alignment on a filing for rexlemestrocel-L for life-threatening major gastrointestinal bleeding in end-stage heart failure patients with left ventricular assist devices.

Mesoblast announced Dr. Gregory George as interim COO while it searches for a full-time COO. Dr. Eric Rose will step away from the Board and focus as Chief Medical Officer. At the November 10, 2026 annual meeting, all listed resolutions carried, including Jon Voigtman’s election and the remuneration, option, restricted stock unit and warrant proposals.

Filing Explained

The interim COO agreement carries annual fixed pay of US$500,000, but ends within six months or when a permanent COO starts, whichever comes first.

The attached company announcement names Dr. Gregory George interim COO while Mesoblast searches for a permanent COO. His full-time agreement sets fixed remuneration at US$500,000 per year and ends at the earlier of six months from commencement or a permanent COO’s start, unless extended by agreement; either side may terminate it at any time.

The terms make him eligible for the employee option plan; any options requiring approval under ASX rules need prior shareholder approval.

The final director-interest notices, dated November 10, 2026, list William Burns with 226,250 ordinary shares held through a custodian and 659,651 options; Eric Rose’s notice lists 6,034,554 ordinary shares, 71,472 ADSs representing 714,720 ordinary shares, and 6,413,451 options.

Key Figures

Net revenue: US$115 million Gross profit, excluding amortization expense: US$110 million Credit-line facility: US$125.0 million +3 more

6 metrics

Net revenue US$115 million FY2026

Gross profit, excluding amortization expense US$110 million On total sales in FY2026

Credit-line facility US$125.0 million Five-year non-dilutive facility; the company said it consolidated and retired two higher-cost facilities

Phase 3 CLBP enrollment 350 patients Enrollment completed in the chronic low back pain trial

Adult SR-aGvHD registration trial 180 adults Grade III/IV patients randomized 1:1 to ruxolitinib or ruxolitinib plus RYONCIL

Reported cardiac mortality reduction 53% DREAM-HF subgroup with HFrEF, Group 2 pulmonary hypertension and active inflammation; p=0.036

Key Terms

Biologics License Application, non-dilutive credit-line facility, Restricted Stock Unit Plan, American Depositary Shares, +2 more

6 terms

Biologics License Application regulatory

"alignment on filing a Biologics License Application"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

non-dilutive credit-line facility financial

"US$125.0 million five-year non-dilutive credit-line facility"

Restricted Stock Unit Plan financial

"approval of the Mesoblast Limited Restricted Stock Unit Plan"

American Depositary Shares financial

"ordinary shares held in the form of American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Orphan Drug designation regulatory

"received Orphan Drug designation"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

endothelial dysfunction medical

"reversing endothelial dysfunction of GI blood vessels"

A condition in which the thin inner lining of blood vessels (the endothelium) no longer works properly, impairing its ability to regulate blood flow, block clots, and control inflammation. Like damage to the inner coating of water pipes that makes them stiff, leaky or prone to clogs, it raises risk for heart attacks, strokes and other vascular problems — making it a key target for drugs, devices and diagnostics that can change clinical outcomes, regulatory decisions and market value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were MESO’s FY2026 net revenue and gross profit?

MESO reported FY2026 net revenue of US$115 million and gross profit on total sales, excluding amortization expense, of US$110 million.

What are the employment terms for MESO’s interim COO?

Dr. Gregory George’s agreement ends at the earlier of six months from commencement or the start of a permanent COO, unless extended by agreement. Either party may terminate it at any time, and fixed remuneration is US$500,000 per annum.

Did MESO shareholders approve the remuneration report?

Yes. The resolution carried, with 72.06% of poll votes for and 27.94% against; abstentions were excluded when determining the majority.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of November 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On November 10, 2026, Mesoblast Limited filed with the Australian Securities Exchange the results of Annual General Meeting, CEO presentation to Annual General Meeting, and the Chair’s Annual General Meeting address, which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, and are incorporated herein by reference.

On November 10, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.4, and is incorporated herein by reference.

On November 10, 2026, Mesoblast Limited filed with the Australian Securities Exchange a Final Director’s Interest Notice (Appendix 3Z), which is attached hereto as Exhibit 99.5 and Exhibit 99.6, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: November 10, 2026

INDEX TO EXHIBITS

Item
99.1						Results of Annual General Meeting, dated November 10, 2026.
99.2						CEO Presentation to Annual General Meeting, dated November 10, 2026.
99.3						Chair’s Annual General Meeting address, dated November 10, 2026.
99.4						Press release of Mesoblast Ltd, dated November 10, 2026.
99.5						Final Director’s Interest Notice, William Burns, dated November 10, 2026.
99.6						Final Director’s Interest Notice, Eric Rose, dated November 10, 2026.

10 November 2026 Mesoblast Limited (MSB) Results of Annual General Meeting Held 10 November 2026 In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as per the attached report. All resolutions were decided by way of a poll. Release authorized by the Chief Executive. Yours faithfully Niva Sivakumar Company Secretary Exhibit 99.1

MESOBLAST LIMITED ANNUAL GENERAL MEETING 2026 Tuesday, 10 November, 2026 RESULT OF ANNUAL GENERAL MEETING 2026 (ASX REPORT) MUFG Corporate Markets A division of MUFG Pension & Market Services As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda. Resolution Voted on at the meeting Proxy Votes (as at proxy close) Total votes cast in the poll (where applicable) No Short Description Strike Y/N/NA For Against Discretionary (OpenVotes) Abstain For Against Abstain ** Result 02 ADOPTION OF THE REMUNERATION REPORT Y 264,807,776 102,910,438 1,023,777 286,745,597 267,999,555 103,906,791 287,245,597 Carried 71.81% 27.91% 0.28% 72.06% 27.94% 03 RE-ELECTION OF MR PHILIP FACCHINA AS A DIRECTOR NA 681,332,113 51,258,694 1,477,740 1,000,461 685,973,208 51,759,694 1,000,461 Carried 92.82% 6.98% 0.20% 92.98% 7.02% 04 ELECTION OF MR JON VOIGTMAN AS A DIRECTOR NA 594,962,346 137,504,499 1,355,946 1,246,217 597,586,218 138,181,117 2,966,028 Carried 81.08% 18.74% 0.18% 81.22% 18.78% 05A APPROVAL OF PROPOSED ISSUE OF OPTIONS TO DR SILVIU ITESCU IN CONNECTION WITH HIS LONG-TERM INCENTIVE REMUNERATION FOR THE 2026/2027 FINANCIAL YEAR NA 312,134,533 49,037,342 672,883 293,642,830 314,189,109 51,318,004 293,644,830 Carried 86.26% 13.55% 0.19% 85.96% 14.04% 05B APPROVAL OF PROPOSED ISSUE OF OPTIONS TO DR SILVIU ITESCU IN CONNECTION WITH HIS SHORT-TERM INCENTIVE REMUNERATION FOR THE 2025/2026 FINANCIAL YEAR NA 338,139,979 23,032,843 680,186 293,634,580 340,203,858 25,313,505 293,634,580 Carried 93.45% 6.37% 0.19% 93.07% 6.93% 06 APPROVAL OF PROPOSED ISSUE OF OPTIONS TO CHIEF MEDICAL OFFICER, DR ERIC ROSE IN CONNECTION WITH HIS LONG-TERM INCENTIVE REMUNERATION FOR THE 2026/2027 FINANCIAL YEAR NA 310,818,275 137,370,402 680,583 206,618,328 313,380,551 139,153,064 206,618,328 Carried 69.24% 30.60% 0.15% 69.25% 30.75% Printed: 10/11/2026 10:48:18 AM This report was produced from the MUFG Pension & Market Services Meeting System Page 1 of 3

MESOBLAST LIMITED ANNUAL GENERAL MEETING 2026 Tuesday, 10 November, 2026 RESULT OF ANNUAL GENERAL MEETING 2026 (ASX REPORT) MUFG Corporate Markets A division of MUFG Pension & Market Services As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda. Resolution Voted on at the meeting Proxy Votes (as at proxy close) Total votes cast in the poll (where applicable) No Short Description Strike Y/N/NA For Against Discretionary (OpenVotes) Abstain For Against Abstain ** Result 07 APPROVAL OF THE MESOBLAST LIMITED RESTRICTED STOCK UNIT PLAN FOR THE PURPOSES OF LISTING RULE 7.2 (EXCEPTION 13) AND THE DEFINITION OF EMPLOYEE SHARE BUY-BACK NA 244,713,623 120,498,466 751,254 287,275,734 247,027,231 121,779,128 287,777,734 Carried 66.87% 32.93% 0.21% 66.98% 33.02% 08A APPROVAL OF PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO MR PHILIP FACCHINA NA 275,863,718 91,462,501 693,973 287,467,396 278,440,384 93,244,163 287,467,396 Carried 74.96% 24.85% 0.19% 74.91% 25.09% 08B APPROVAL OF PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO MS LYN COBLEY AM NA 270,350,218 90,400,491 683,143 294,053,736 272,916,054 92,182,153 294,053,736 Carried 74.80% 25.01% 0.19% 74.75% 25.25% 08C APPROVAL OF PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO MS JANE BELL AM NA 270,380,698 177,702,357 683,143 206,721,390 272,946,534 179,484,019 206,721,390 Carried 60.25% 39.60% 0.15% 60.33% 39.67% 08D APPROVAL OF PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO DR GREGORY GEORGE NA 276,334,555 91,150,913 673,143 287,328,977 279,239,044 92,583,922 287,328,977 Carried 75.06% 24.76% 0.18% 75.10% 24.90% 08E APPROVAL OF PROPOSED ISSUE OF RESTRICTED STOCK UNITS TO MR JON VOIGTMAN NA 226,840,465 140,320,963 673,143 287,653,017 228,293,293 142,666,625 288,192,025 Carried 61.67% 38.15% 0.18% 61.54% 38.46% Printed: 10/11/2026 10:48:18 AM This report was produced from the MUFG Pension & Market Services Meeting System Page 2 of 3

MESOBLAST LIMITED ANNUAL GENERAL MEETING 2026 Tuesday, 10 November, 2026 RESULT OF ANNUAL GENERAL MEETING 2026 (ASX REPORT) MUFG Corporate Markets A division of MUFG Pension & Market Services As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda. Resolution Voted on at the meeting Proxy Votes (as at proxy close) Total votes cast in the poll (where applicable) No Short Description Strike Y/N/NA For Against Discretionary (OpenVotes) Abstain For Against Abstain ** Result 09 APPROVAL OF PROPOSED ISSUE OF WARRANTS TO DR GREGORY GEORGE NA 393,701,997 52,828,899 692,643 287,845,469 396,794,904 54,092,990 287,845,469 Carried 88.03% 11.81% 0.15% 88.00% 12.00% ** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item Printed: 10/11/2026 10:48:18 AM This report was produced from the MUFG Pension & Market Services Meeting System Page 3 of 3

Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases November 2026 ASX: MSB; Nasdaq: MESO Annual General Meeting 2026 Exhibit 99.2

2 This presentation includes forward-looking statements and forecasts that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events , recent changes in regulatory laws, and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. These statements may relate to, but are not limited to: expectations with respect to sales and revenue, expectations regarding the safety or efficacy of, or potential applications for, Mesoblast's adult stem cell technologies; expectations regarding the strength of Mesoblast's intellectual property, the timeline for Mesoblast's regulatory approval process, and the scalability and efficiency of manufacturing processes; expectations about Mesoblast's ability to grow its business and statements regarding its relationships with current and potential future business partners and future benefits of those relationships; statements concerning Mesoblast's share price or potential market capitalization; and statements concerning Mesoblast's capital requirements and ability to raise future capital, among others. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this presentation together with our financial statements and the notes related thereto, as well as the risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, include, without limitation: risks inherent in the development and commercialization of potential products; uncertainty of clinical trial results or regulatory approvals or clearances; government regulation; the need for future capital; dependence upon collaborators; and protection of our intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Cautionary Note Regarding Forward Looking Statements

To be the world’s leading and most innovative cellular medicines company To use our proprietary technologies to develop cellular medicines that are life-saving and that transform lives To be an organisation that displays efficiency and attracts highly motivated professionals working towards a common goal To deliver appropriate returns for our shareholders Corporate Vision

4 FY2026: Highlights for the Year and Delivery of Major Milestones Successful first year for U.S. commercial launch of RYONCIL • FY2026 net revenue US$115M • Gross profit on total sales, excluding amortization expense, was US$110M Major milestones achieved ✓ Completed 350 patients treated in the Phase 3 trial for the blockbuster chronic low back pain (CLBP) indication ✓ Alignment with FDA on filing for approval in end-stage heart failure indication ✓ Registration trial for label extension of RYONCIL into adults with SR-aGvHD has commenced and is currently enrolling patients, targeting 40 sites across the U.S. ✓ Pediatric Duchenne’s Phase 3 IND cleared by FDA ✓ Entered into a US$125.0 million five-year non-dilutive credit-line facility, consolidating and retiring two higher cost facilities SR-aGvHD = Steroid-Refractory Acute Graft versus Host Disease IND = Investigational New Drug | MSC = Mesenchymal Stromal Cell | FDA = United States Food & Drug Administration

5 ✓ Global IP portfolio >1,100 patents and patent applications provide protection through >2044 ✓ Dominant IP underpins a scalable commercial business model for cell therapy products ✓ First mover advantage – RYONCIL is the first and only MSC approved by FDA ✓ Leverage FDA Guidance to obtain label extensions for RYONCIL in other indications ✓ Completed large, US-based, randomized clinical trials which provide evidence of efficacy across multiple platforms ✓ Leader in cell manufacturing with IP protection, significant know-how advantage, demonstrated FDA alignment, scale-up capacity, and ability to leverage across many products ✓ Next gen technology leadership to enhance tissue-homing characteristics and achieve even greater efficacy in inflammatory diseases ✓ Executive leadership with proven capability to bring cutting-edge cell therapy technology to market Our ‘MOAT’ – Our Market Leadership Position IP = Intellectual Property | MSC = Mesenchymal Stromal Cell | FDA = United States Food & Drug Administration

6 Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies Ryoncil® Only FDA Approved MSC, Successful First US Launch Net revenue US$115M in FY2026 – first full year post launch Highly profitable single product on stand-alone basis Opportunities in adult aGvHD and other severe pediatric inflammatory diseases, such as Duchenne muscular dystrophy, with similar MOA Rexlemesteocel-L the Engine for Blockbuster Opportunities Rexlemestrocel-L provides late- stage opportunities to disrupt massive pain and cardiovascular markets with substantial unmet medical needs • Chronic low back pain • Pulmonary hypertension in left heart failure Commercial Capability Infrastructure to support product launches across multiple indications Sales & market access team focused on transplant centers and specialists • >50 centers onboarded • 98% US lives covered • J-code obtained aGvHD = Acute Graft-versus–Host Disease | MSC = Mesenchymal Stromal Cell | FDA = United States Food & Drug Administration | MOA = Mechanism of Action

7 Operational Management • Search for US-based Chief Operating Officer (COO) to prepare for commercial manufacturing scale-up and potential commercial launch activities for rexlemestrocel-L • Dr. Greg George will be Interim COO, with extensive operational experience having founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development (>250 centers across more than 30 States) • Dr. Eric Rose will focus his efforts as Chief Medical Officer on advancing the transformational opportunities for rexlemestrocel-L in our cardiopulmonary franchise and will step away from Board activities Board of Directors • Global search for additional directors with biopharma, manufacturing and commercial expertise • Jon Voigtman, subject to approval by shareholders, will join the Board • William Burns and Philip Krause retire from the Board Management and Board Expanding operational management to augment commercial preparedness of our second-generation product rexlemestrocel-L in the blockbuster indications of inflammatory chronic low back pain and cardiovascular disease

8 Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio Assets Wholly Owned and Unencumbered in U.S. Markets SR-aGvHD = Steroid-Refractory Acute Graft versus Host Disease | HFrEF = Heart Failure with Reduced Ejection Fraction | CLBP = Chronic Low Back Pain | TAM = Total Addressable Market This chart is figurative and does not purport to show individual trial progress within a clinical program Notes: ▪ JCR Pharmaceuticals Co., Ltd. (JCR), has the right to develop mesenchymal stromal cells (MSCs) in certain fields for the Japanese market, including for the treatment of hematological malignancies, such as Graft vs Host Disease, and for hypoxic ischemic encephalopathy (HIE). ▪ Grünenthal has an exclusive license to develop and commercialize rexlemestrocel-L for chronic low back pain in Europe and Latin America/Caribbean. ▪ Tasly Pharmaceuticals has exclusive rights for rexlemestrocel-L for the treatment or prevention of chronic heart failure in China. TAM ~US$1B TAM >US$1B TAM >US$1B TAM >US$10B TAM >US$10B

9 RYONCIL® Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

10 • >2,000 adults annually in U.S. with SR-aGvHD of which ~50% have Grade III/IV disease • Registration trial: 180 Grade III/IV SR-aGvHD adults randomized 1:1 to ruxolitinib vs ruxolitinib + RYONCIL • Primary endpoint Day 28 overall response; secondary endpoint Day 180 overall survival • Targeting ~40 U.S. centers, representing >50% of annual allo transplants performed • Expected duration 18-24 months, with interim analysis for potential early success Potential Market for RYONCIL Label Extension as Part of Second-line Regimen Combined with Ruxolitinib in Adults with Grade III/IV aGvHD Interim analysis planned for early success when first 102 patients (57% enrolled) have reached Day 28 (primary endpoint) Analysis expected Q4 CY2027 57% SR-aGvHD = Steroid-Refractory Acute Graft versus Host Disease

Rexlemestrocel-L Chronic Low Back Pain due to Degenerative Disc Disease (CLBP)

12 Phase 3 trial to Reduce Inflammation & Pain in Degenerative Disc Disease Targeted, minimally invasive delivery of rexlemestrocel-L to the degenerated disc Healthy disc • Hydrated nucleus • Intact annulus • Minimal nerve ingrowth Major Milestones to Commercial Launch 1 P3 trial 350 patients fully enrolled 2 Primary endpoint: 12-month pain reduction Secondary endpoint: improved function 3 Trial readout H2 CY2027followed by BLA filing 4 Potential approval CY2028 McCann MR and Seguin CA. J. Dev. Biol. 2016, 4(1), 3. Degenerated disc • Loss of disc height & hydration • Inflammation • Nerve & blood vessel ingrowth • Associated with chronic pain P3 = Phase 3 | BLA = Biologics License Application

13 The Patient Treatment Journey ~7M US patients have moderate / severe DDD within 5 years of diagnosis that is refractory to medical therapies including opioids Rexlemestrocel-L targeting moderate-to-severe CLBP NSAIDs Physical therapy Chiropractic treatments Acupuncture Anticonvulsants (e.g., gabapentin) Epidural steroid injections (off-label) Radio frequency ablation Spinal cord stimulation Intrathecal pumps Conservative Treatments Opioid Analgesics Weak opioid analgesics (e.g., tramadol) Strong opioid analgesics (e.g., oxycodone) Interventional Therapies Surgery Spinal fusion Disc replacement CLBP = Chronic Low Back Pain | DDD = Degenerative Disc Disease

14 Pain Specialists are the Dominant Caregivers Seen by Patients with CLBP Primary Care Physician (50%) Other (Ortho-/Spine Surgeon, Neurosurgeon, Rehabilitative Medicine Specialist, and Interventional Radiologist) (10%) Patient Presents With Symptoms Pain Specialist or Anesthesiologist (40%) • Physical exam • Pain scales • Imaging (MRIs, X- rays) • Imaging • Facet joint blocks (nerve blocks) • Discography • Imaging • Facet joint blocks (nerve blocks) • Discography Stakeholder Diagnostic Modalities CLBP = Chronic Low Back Pain | DDD = Degenerative Disc Disease

15 Pain Specialist Neurosurgeon Ortho Surgeon 8% 8% 31% 8% 8% 31% 18% 31% 23% 69% 55% 15% 15% 8% 9% 31% 8% 18% 8% Likelihood of Recommendation Irrespective of Price: Pain and Function Data at 12 Months 50-74% likely25-49% likely1-24% likely0% likely 75-99% likely 100% likely Anesthesiology Guidehouse 2021 Study 85% of Pain Specialists are More Likely to Recommend Rexlemestrocel-L for CLBP Based on Outcomes from First Phase 3 Trial CLBP = Chronic Low Back Pain | DDD = Degenerative Disc Disease

Rexlemestrocel-L Heart Failure

17 Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism LVAD BLA approval for rexlemestrocel-L can open label extension potential in two additional blockbuster indications with same mechanism of action Intra-Myocardial Rexlemestrocel-L Reduces Inflammation And Reverses Endothelial Dysfunction Reduces M1 Macrophage and T Cell Burden (IL-1β, IL-6, IL-12 and IFN-γ) Improves endothelial dysfunction / NO signaling Improves Left Ventricular Function Improves Pulmonary Arterial Hypertension And Right Ventricular Function Group 2 Pulmonary Hypertension (HFrEF, HFpEF) PH with inflammation in HFrEF DREAM-HF 565 patient trial: Improved diastolic function, pulmonary hypertension and survival NYHA Class II/III HFrEF NYHA class II/III HFrEF with inflammation DREAM-HF 565 patient trial: Reduction in cardiac death, MI, stroke End-Stage HFrEF with LVAD End-stage HFrEF with inflammation LVAD 159 Patient trial: Reduction in major GI bleeding and RV dysfunction LVAD = Left Ventricular Assist Device | BLA = Biologics License Application | HFrEF = Heart Failure reduced Ejection Fraction | HFpEF = Heart Failure preserved Ejection Fraction | NYHA = New York Heart Association | GI = Gastrointestinal | MACE = Major Adverse Cardiac Event | MI = Myocardial Infarction | PH = Pulmonary Hypertension | NO = Nitric Oxide

18 • File with FDA for full approval for rexlemestrocel-L in patients with LVADs • Major GI Bleeding is an FDA-acknowledged indication with rexlemestrocel-L having received Orphan Drug designation • FDA has confirmed at a recent meeting that the BLA filing may proceed for patients with life- threatening major gastrointestinal bleeding Subjects from LVAD II Study Control (MMBE rate/100 patient months) Rexlemestrocel-L (MMBE rate/100 patient months) Nominal p value All subjects (N=159) 15.6 3.8 <0.0001 Destination Therapy (n=59) 20.4 2.5 0.0007 Bridge to Transplant (n=100) 12.9 4.6 0.0172 LVAD II: 6-Month Rate of Major Mucosal Bleeding Events (MMBE) GI = Gastrointestinal | HFrEF = Heart Failure reduced Ejection Fraction | LVAD = Left Ventricular Assist Device | MMBE = Major Mucosal Bleeding Events | ITT = Intention to Treat Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs by Reversing Endothelial Dysfunction of GI Blood Vessels Due to Inflammation

19 Group 2 Pulmonary Hypertension (Due to LV Dysfunction) Left-heart disease raises pulmonary pressure and right ventricular load Left-heart disease Pulmonary venous hypertension Right ventricular strain LV or valve disease raises left atrial pressure Pressure backs up into lung veins and capillaries Higher pulmonary pressure increases RV afterload 9 LV = Left Ventricular | RV = Right Ventricular

20 Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension in DREAM-HF Trial • In the DREAM-HF population with HFrEF, 219 patients had established Group 2 Pulmonary Hypertension, defined by pulmonary artery systolic pressure (PASP) >35 mmHg, • Across all 219 patients, a single intra-cardiac injection of rexlemestrocel-L improved left ventricular diastolic function as measured by Doppler echocardiography • A single intra-cardiac injection of rexlemestrocel-L reduced Left Atrial Volume Index (LAVI) over 36 months, a major risk factor for mortality related to Pulmonary Hypertension in both HFrEF and HFpEF • A single intra-cardiac injection of rexlemestrocel-L reduced cardiac mortality by 53% in HFrEF patients with Type 2 Pulmonary Hypertension and active inflammation defined by CRP >2 mg/L (p=0.036) HFrEF = Heart Failure reduced Ejection Fraction | CRP = C-reactive Protein | HFpEF = Heart Failure preserved Ejection Fraction

21 Group 2 PH: A Large Unmet Need with No Approved Drugs Left heart disease is the most common cause of pulmonary hypertension, creating a substantial addressable population 2 GROUP 2 PH - CLINICAL CONTEXT Most common PH group Approximately 40% of left-sided heart failure No approved drug therapy Total Addressable Market for Rexlemestrocel-L Illustrative patient funnel | United States 6.5M total heart failure patients 3.0M HFrEF | 3.5M HFpEF ~35% have sPAP >35 mmHg 1.05M HFrEF | 1.225M HFpEF ~50% have CRP ≥2 0.5M HFrEF | 0.6M HFpEF Potential target population: ~1.1M patients 21 No drugs currently used for HFrEF or HFpEF have any effect on Group 2 PH, nor do any approved drugs for other forms of PH PH = Pulmonary Hypertension | HFrEF = Heart Failure reduced Ejection Fraction | CRP = C-reactive Protein | HFpEF = Heart Failure preserved Ejection Fraction | sPAP = Systolic Pulmonary Artery Pressure

22 Next Generation Technologies CAR-MSC mesoblast 22

23 The Future: Genetically-Modified CAR-MSC Platform • Leverage technology behind CAR-T therapies without issues re: (i) safety and (ii) manufacturing • Broad range of potential target antigens/intracellular pathway choices • Enhanced targeting results in increased potency • Lead products target Lupus and UC/Crohn’s, significant/unmet medical needs (A) Chimeric antigen receptor (CAR) targeting specific disease-associated antigen (B) Binding to antigen triggers selected intracellular pathway to enhance potency (C) Retain native properties of MSCs (A) (B) (C) CAR = Chimeric Antigen Receptor | MSC = Mesenchymal Stromal Cell | UC = Ulcerative Colitis

24 In Summary

25 Summary of Major Milestones Commercial growth and label expansion for RYONCIL, alongside advancement of rexlemestrocel-L blockbuster programs 1 COMMERCIAL + LABEL EXPANSION RYONCIL® (remestemcel-L-rknd) GROW Strongly expand the revenue base and increase penetration of pediatric SR-aGvHD EXPAND Complete adult SR-aGvHD registrational trial in second-line Grade III/IV EXTEND Advance pediatric inflammatory rare diseases, including Duchenne, and pursue partnerships Adult SR-aGvHD market is ~3× the pediatric market 2 BLOCKBUSTER PROGRAM Chronic low back pain (CLBP) COMPLETED Patient treatment completed in the pivotal Phase 3 trial in August READOUT Continue patient follow-up through 12 months FILE Trial completion targeted for mid- CY2027, followed by BLA filing Pivotal Phase 3 program progressing toward BLA 3 BLOCKBUSTER PROGRAM Advanced & End-stage heart failure (CHF) FILE Complete BLA filing for end-stage heart failure patients on LVADs EXTEND Facilitate label extensions into Pulmonary Hypertension and NYHA II/III HFrEF PARTNER Pursue cardiopulmonary strategic alliance LVAD filing can establish the regulatory foundation SR-aGvHD = Steroid-refractory Acute Graft-versus-Host Disease | BLA = Biologics License Application | LVAD = Left Ventricular Assist Device | HFrEF = Heart Failure reduced Ejection Fraction | NYHA = New York Heart Association 25

Thank You

CHAIR’S ADDRESS TO SHAREHOLDERS 2026 ANNUAL GENERAL MEETING Good morning, ladies and gentlemen, fellow shareholders, members of the Board, our management team and global staff. My name is Phil Facchina, I am the Chairman of the Mesoblast Board of Directors, and it is my pleasure to welcome you to the 2026 Annual General Meeting. On behalf of the Board, I’d like to thank our shareholders for their continued confidence and support. In particular we thank those of you who have stood by the company through the many years of scientific development, regulatory challenges, and the substantial investments that have funded the Company’s ambition to revolutionize cellular medicine. Today as I stand before you, Mesoblast is at a defining and transformative point. Prior to 2025, the Company was exclusively focused on the research aspects of developing innovative cellular therapies, working to demonstrate the clinical benefits of each, and navigating the complex regulatory pathways necessary to bring these treatments to patients. Over many years, the Company’s efforts have required extraordinary perseverance, significant financial resources, and an unwavering belief in the potential of its technology. In fiscal 2026, among other things, we continued our development by: • Completing enrollment in the pivotal Phase 3 trial of rexlemestrocel-L to treat chronic low back pain; • We began enrollment in our registrational trial to expand Ryoncil® (remestemcel-L-rknd) to the adult population; and, • We continued our work on heart-related treatments. Commercially, the regulatory approval and availability of RYONCIL beginning in late fiscal 2025, allowed Mesoblast to take an important step forward. In fiscal 2026, we made additional commercial progress, with RYONCIL generating approximately US$115 million in net product sales. We are transitioning from a company whose value had been driven exclusively by its scientific progress and the potential of its clinical pipeline to one that must increasingly be focused on commercial execution, revenue generation, and financial performance. This transition represents both an extraordinary opportunity and a fundamental change in how Mesoblast operates, executes and measures its success. Scientific innovation will always remain at the heart of Mesoblast; however, our future success will be determined by our ability to: • Execute commercially; • Expand the product portfolio; • Navigate a dynamic regulatory framework; and, • Allocate and manage resources efficiently. The Board recognizes that this transition requires an intense focus on: • Operational excellence; • Disciplined capital allocation; and, • Financial accountability. Exhibit 99.3

Our priorities are clear: First, we must successfully commercialize our approved therapies, ensuring that patients who can benefit from these treatments have prompt access to them. This requires continuing investments in improved and more efficient manufacturing, supply chain, and distribution capabilities as well as the commercial infrastructure necessary to support sustainable growth. We learned a lot during our first full year of sales, but there is still much to learn and many improvements to be made in order to fully capitalize on our current commercial opportunity. Second, we must continue to invest in our robust product portfolio with an emphasis on those opportunities that offer defined clinical benefits, attractive commercial markets, and the potential to create meaningful shareholder value. Both our near and long-term pipelines offer significant potential for very material value creation. As we prioritize our opportunities, we will invest in those with the most potential both clinically and financially. We will make decisions to either retain assets independently or to seek strategic partners, as appropriate. Simply stated, we will take every action necessary to convert our development pipeline into approved commercially successful products. Third, we must maintain financial discipline. Allocating capital between commercial opportunities and a robust pipeline can be challenging. Our RYONCIL sales will supplement much of our clinical development, but the balance between commercial success and clinical development must be reconciled so Mesoblast can be successful on both fronts. Finally, we must remain firmly focused on delivering returns to you, our shareholders. You have provided the capital, patience, and confidence necessary to support Mesoblast through an exceptionally challenging development journey. We recognize that this commitment deserves more than scientific progress alone. You deserve a company capable of translating its scientific leadership into commercial success, sustainable financial performance, and long-term shareholder value. The challenges ahead are not insignificant and they must be met with rigor. As Chairman, I want to assure all shareholders that the Board is fully committed to overseeing the transition from a purely clinical company into a commercial successful company. The Board will hold itself and management accountable for execution in an effort to ensure that our strategic and financial decisions are aligned with the long-term interests of you, our shareholders. I would like to acknowledge our Chief Executive Officer, Dr. Silviu Itescu. Silviu’s vision, perseverance and relentless pursuit of transformative research has been essential in bringing Mesoblast to this stage. I thank our management team and our employees for their dedication, commitment and their willingness to embrace the challenges of both clinical development and commercialization. I would also like to thank my fellow directors for their contributions and our shareholders for their continued support. Specifically: • I’d like to recognize the many contributions and counsel of Bill Burns as a Director and Vice-Chair over the past thirteen years. Bill has continually lent his guidance and insight to both the Board and management; • I’d also like to thank Dr. Phil Krause for his time and effort in working with the Company to the successful commercial approval of RYONCIL; • I’d like to particularly thank Dr. Eric Rose for his contributions to the Board and his willingness to actively step in and assist the Company during very challenging times; • As part of the evolution of the Board, I am pleased to welcome Jon Voigtman, who is standing for election as a Director at today’s meeting, and, subject to shareholder approval, we look forward to Jon’s contribution as Mesoblast enters its next phase of growth. As we prepare for the next phase of Mesoblast’s evolution, we plan to add the necessary capabilities to both the Board and to management, required to take the Company successfully into the future. Specifically, our search for additional talent is focused on the twin goals of clinical success and commercial execution, both of which we are now held accountable. As we look ahead, our message is straightforward: Mesoblast has demonstrated the potential of its science. We must build on that scientific foundation, execute with discipline, and translate the opportunities before us into measurable commercial and financial results.

The Board is committed to ensuring that the next chapter of Mesoblast is characterized not only by continued innovation, but also by commercial achievement, financial strength, and the creation of lasting value for our shareholders. We plan to embrace the opportunities and challenges that lie ahead. Thank you all for your continued confidence in Mesoblast. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of

Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au

MESOBLAST EXPANDS OPERATIONAL MANAGEMENT TO DRIVE BLOCKBUSTER POTENTIAL OF REXLEMESTROCEL-L IN BACK PAIN AND CARDIOVASCULAR DISEASE New York, USA: November 9 and Melbourne, Australia: November 10, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it is expanding its operational management to augment commercial preparedness for the second-generation product rexlemestrocel-L in the blockbuster indications of inflammatory chronic low back pain (CLBP) and cardiovascular diseases. These indications have completed Phase 3 programs and are in line for important readouts and U.S Food and Drug Administration (FDA) filings. Chief Executive Dr. Silviu Itescu said: “With growing revenues from our first FDA-approved product Ryoncil® (remestemcel-L-rknd), we are now expanding operational management to ensure the success of our second-generation rexlemestrocel-L products with market disrupting potential. This platform becomes the engine for scientific innovation, revenue growth and shareholder value.” A successful outcome of the CLBP Phase 3 trial readout during the second half of calendar 2027 will underpin one of the most valuable commercial opportunities in our portfolio. As such a primary corporate objective is to prepare for commercial manufacturing scale-up and potential commercial launch activities for the CLBP product. While the Company undertakes a search for a full-time Chief Operating Officer (COO) to support these activities, Dr. Gregory George will act in an interim COO capacity. Dr George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George said: “I am looking forward to my role as interim COO. My immediate focus will be on driving operational efficiencies, accelerating the commercialization of our innovative cell therapies, and building a scalable, profitable business that delivers long-term value to patients and shareholders.” Mesoblast recently met with FDA and obtained alignment on filing a Biologics License Application for rexlemestrocel-L to reduce life-threatening major gastrointestinal bleeding in end-stage heart failure patients being kept alive by a left ventricular assist device (LVAD). Mesoblast’s strategy for entering the cardiovascular market is to obtain approval for rexlemestrocel-L in these patients and then expand the label to moderate/severe heart failure, including the new opportunity in patients with life-threatening pulmonary hypertension. The common thread between these patient populations is severe inflammation and endothelial dysfunction which affects the arteries in the heart, the lungs and the gastrointestinal tract. Dr. Eric Rose will focus his efforts as Chief Medical Officer on advancing the transformational opportunities for rexlemestrocel-L in our cardiopulmonary franchise and will step away from the Board. As a world-renowned heart surgeon and scientist, Dr. Rose performed the world’s first successful pediatric heart transplant. As Chairman of Columbia University’s Department of Surgery his scientific leadership resulted in the first FDA approval of an implantable LVAD for long term circulatory support, spawning an entire new industry. About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved Exhibit 99.4

mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast References / Footnotes 1. Please see the full Prescribing Information at www.ryoncil.com Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive.

For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au

Annexure - Summary of material terms of employment agreement with Interim Chief Operating Officer provided in accordance with ASX Listing Rule 3.16.4 The full-time employment agreement with the new Interim Chief Operating Officer Dr. Gregory George who is a Mesoblast Director, is for a term ending on the earlier of six months from commencement and the commencement of a permanent Chief Operating Officer (unless extended by agreement), and Mesoblast or Dr. George may terminate the employment agreement at any time. The Chief Operating Officer role reports to the Chief Executive. Total fixed remuneration is US$500,000 per annum. Dr. George will be eligible to participate in Mesoblast's employee share option plan as a component of his remuneration. To the extent required under the ASX Listing Rules, any options to be granted to him as part of his remuneration will require prior shareholder approval. More information on Mesoblast's employee share option plan for its executives can be found in the Remuneration Report set out on pages 105 to 135 of the Company's 2026 Annual Report.

Appendix 3Z Final Director’s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Mesoblast Limited ABN 68 109 431 870 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director William Burns Date of last notice 28 October 2025 Date that director ceased to be director 10 November 2026 Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Number & class of securities 659,651 options, held directly Exhibit 99.5

Appendix 3Z Final Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Z Page 2 11/3/2002 Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest Registered holders is UBS (as custodian for the director) Number & class of securities 226,250 ordinary shares Part 3 – Director’s interests in contracts Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable No. and class of securities to which interest relates Not applicable

Appendix 3Z Final Director’s Interest Notice + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Mesoblast Limited ABN 68 109 431 870 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director Dr Eric Rose Date of last notice 20 March 2026 Date that director ceased to be director 10 November 2026 Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Number & class of securities 6,034,554 ordinary shares 6,413,451 options Exhibit 99.6

Appendix 3Z Final Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Z Page 2 11/3/2002 Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest Interest in ordinary shares held in the form of American Depositary Shares (“ADSs”) held by custodian JP Morgan Nominees Australia Pty Limited. Number & class of securities 71,472 American Depositary Shares representing 714,720 ordinary shares Part 3 – Director’s interests in contracts Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable No. and class of securities to which interest relates Not applicable

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EX-99.1 7.1 KB
• EX-99.2 EX-99.2 27.6 KB
• EX-99.3 EX-99.3 15.0 KB
• EX-99.4 EX-99.4 11.8 KB
• EX-99.5 EX-99.5 3.3 KB
• EX-99.6 EX-99.6 3.4 KB